Salvia BioElectronics raises $60M Series B to complete migraine implant clinical program
Summary
Eindhoven-based Salvia BioElectronics raised $60M in a Series B to complete clinical development and prepare commercial launch of their implantable closed-loop neurostimulation device for drug-resistant chronic migraine. The device detects cortical spreading depolarization biomarkers — the neural signature of migraine attacks — and delivers preemptive stimulation to abort attacks before they become symptomatic. This is Salvia's largest funding round and brings total raised to over $100M.
Why it matters
Salvia's $60M Series B positions them as the best-funded migraine implant company globally. The closed-loop detection-and-abort approach is mechanistically superior to blind prophylactic stimulation and, if it works, could be the first treatment that actually prevents migraines rather than treating them after onset.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial